Sickle cell disease causes accelerated kidney function decline, yet proven GFR-preserving therapies remain elusive. In this study of adults with sickle cell disease, RASi use was not associated with a significant difference in the rate of eGFR decline.
Altri episodi di "Kidney360"



Non perdere nemmeno un episodio di “Kidney360”. Iscriviti all'app gratuita GetPodcast.








